1 research outputs found
Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer
Bladder cancer is one of the most common malignancies
in the urinary
system, with high risk of recurrence and progression. However, the
difficulty in detecting small tumor lesions and the lack of selectivity
of intravesical treatment seriously affect the prognosis of patients
with bladder cancer. In the present work, a nanoparticle-based delivery
system with tumor targeting, high biocompatibility, simple preparation,
and the ability to synergize imaging and therapy was fabricated. Specifically,
this nanosystem consisted of the core of doxorubicin (DOX)-loaded
polydopamine nanoparticles (PDD NPs) and the shell of hyaluronic acid
(HA)-conjugated IR780 (HA-IR780). The HA-IR780-covered PDD NPs (HR-PDD
NPs) demonstrated tumor targeting and visualization both in vitro
and in vivo with properties of promoted cancer cell endocytosis and
lysosomal escape, efficiently delivering drugs to the target site
and exerting a killing effect on tumor cells. Encouragingly, intravesical
instillation of HR-PDD NPs improved drug retention in the bladder
and promoted its accumulation in tumor tissue, resulting in better
tumor proliferation inhibition and apoptosis in an orthotopic bladder
cancer model in rats. This study provides a promising strategy for
the diagnosis and therapy of bladder cancer